RaySearch Laboratories AB (publ) Interim report January 1 - September 30, 2009

RaySearch Laboratories AB (publ) Interim report January 1 - September 30, 2009

JANUARY 1 - SEPTEMBER, 30 2009 
•	Net sales for the period amounted to SEK 47.3 M (41.3) 
•	Profit after tax was SEK 12.6 M (7.3) and earnings per share amounted to SEK
0.37 (0.21) 
•	Operating profit was SEK 17.1 M (8.0) 
•	Cash flow totaled SEK 5.4 M (neg: 20.0) 
•	The first product from the collaboration with TomoTherapy received FDA
clearance in January and has been launched
•	Three products from the collaboration with Varian were launched in June
•	Breakthrough order for proton treatment planning system was secured in June 
•	Two new products from the collaboration with Nucletron were launched in
September

AFTER THE END OF THE PERIOD
•	The new VMAT product from the collaboration with Philips began generating
revenues in November
•	The collaboration agreement with Siemens, which was signed in May, was
expanded and accelerated in November



“It is extremely satisfying that the major development efforts during recent
years are now beginning to pay off. In November our new product for Philips
started generating revenues and we anticipate that the total revenue
contribution from this and other new products will exceed SEK 10 M already in
the fourth quarter,” says Johan Löf, President of RaySearch.

“We have also expanded and accelerated our collaboration with Siemens which is
now expected to start generating revenues in the second half of 2010 instead of
in 2011 as previously stated. Consequently, I can say that the potential for
growth has never looked as favorable as it does now,” concludes Johan Löf.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Johan Löf, President and CEO
Tel: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

ABOUT RAYSEARCH

RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners, such as
Philips, Varian, Siemens, Nucletron, IBA Dosimetry and TomoTherapy. To date, 15
products have been launched and RaySearch's software is used at about 1,500
clinics in more than 30 countries. In addition, existing license agreements
cover more than 15 other products that are scheduled to be launched in the
coming years. RaySearch was founded in 2000 as a spin-off from Karolinska
Institutet in Stockholm and the company is listed in the Small Cap segment of
NASDAQ OMX Nordic Exchange Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com.